Tregs have been shown to promote hyper-progression of cancer after programmed cell death protein 1 (PD1) therapy in a fraction of patients with gastric cancer due to the amplification of PD1+ Tregs, which are highly suppressive (1). This evidence concerns the gene PDCD1 and gastric cancer.